Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ERBB3 |
| Variant | T389K |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | ERBB3 (HER3) T389K lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). T389K confers a gain of Erbb3 (Her3) protein function, resulting in phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2) expressing cells (PMID: 23680147). |
| Associated Drug Resistance | |
| Category Variants Paths |
ERBB3 mutant ERBB3 act mut ERBB3 T389K |
| Transcript | NM_001982.4 |
| gDNA | chr12:g.56092803C>A |
| cDNA | c.1166C>A |
| Protein | p.T389K |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001982.3 | chr12:g.56092803C>A | c.1166C>A | p.T389K | RefSeq | GRCh38/hg38 |
| NM_001982.4 | chr12:g.56092803C>A | c.1166C>A | p.T389K | RefSeq | GRCh38/hg38 |
| NM_001982 | chr12:g.56092803C>A | c.1166C>A | p.T389K | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 T389K | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) T389K (PMID: 23680147). | 23680147 |
| ERBB3 T389K | Advanced Solid Tumor | sensitive | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, Herceptin (trastuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) T389K in culture (PMID: 23680147). | 23680147 |
| ERBB3 T389K | Advanced Solid Tumor | sensitive | Pertuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, Perjeta (pertuzumab) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) T389K in culture (PMID: 23680147). | 23680147 |
| ERBB3 T389K | Advanced Solid Tumor | sensitive | Pictilisib | Preclinical - Cell culture | Actionable | In a preclinical study, Pictilisib (GDC-0941) inhibited cell proliferation in transformed cell lines expressing ERBB3 (HER3) T389K in culture (PMID: 23680147). | 23680147 |